LivIQ leadless pacemaker system for ventricular pacing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open‑label, prospective, single‑arm international study enrolling 325 subjects across up to 60 centers in the U.S., Europe, and Asia‑Pacific. Eligible adults with a Class I or II indication for ventricular pacing are enrolled after medical‑record review and informed consent and receive the LivIQ leadless pacemaker. Participants are seen at implant, pre‑discharge, 1, 3, 6, and 12 months and then every 6 months until regional market approval, with a required remote 24‑month check after U.S. approval. An integrated atrioventricular synchrony (AVS) sub‑study collects Holter data at 1 and 6 months to test VDD pacing performance.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Class I or Class II indication for ventricular pacing (VVI/VDD) according to applicable guidelines
2. Age is greater than or equal to 18 years at time of consent
3. Able to understand the nature of the study and provide written informed consent
4. Able and willing to complete all study requirements, including completion of all planned in-office study visits, for the expected duration of follow-up

Exclusion criteria:

1. AV block with a ventricular escape rhythm ≤ 30 bpm at time of consent Note: Restriction removed after early safety phase objectives are met
2. Femoral venous anatomy that is unable to accommodate the introducer or the cardiac anatomy does not allow a leadless pacemaker in the right ventricle
3. Morbid obesity which may prevent the LivIQ device from obtaining telemetry communication within a range of 20 cm, in the physician's judgement
4. Intolerance of dexamethasone acetate
5. Other implanted devices that, in the judgement of the implanting physician, could interfere (mechanically or electrically) with the leadless pacemaker or with the implant procedure
6. Allergy to the materials of the leadless pacemaker or the implant tools that are in contact with the human body
7. Prior leadless pacemaker implant attempt
8. Existing transvenous or leadless pacemaker, transvenous or subcutaneous ICD, or CRT device or previous extraction in which transvenous leads (full or partial) were left in the heart Note: Exception given to use temporary transvenous pacemakers
9. CIED device extraction within the previous 72 hours or signs of active infection after CIED extraction Note: Patients with extraction due to potential systemic infection must have a blood culture. A blood culture is considered negative if there is no growth within 72 hours prior to the LivIQ implant.
10. Planned ICD or CRT device implant
11. Unstable angina pectoris or acute myocardial infarction within 30 days prior to enrollment
12. Life expectancy of less than 12 months
13. Unable to tolerate an urgent sternotomy
14. Planned right-sided heart intervention within 30 days after implant Note: Exception given to AV nodal ablations when performed by an implanting investigator once early safety phase objectives are met
15. Listed for or has received a heart transplantation or has a left ventricular assist device (LVAD)
16. Participation or plan to participate in any other potentially confounding investigational drug or device trial, or any other clinical trial that may interfere with this study's treatment or protocol during the duration of the study Note: Co-enrollment in concurrent trials is only allowed when documented prior approval is obtained from BIOTRONIK
17. Unable to attend in-person planned or emergent study site visits (e.g., frequent or extended travel plans)
18. Pregnant or plan to become pregnant during the duration of the study

AVS Sub-Study Inclusion Criteria:

After consenting to the main study, patients potentially eligible for the AVS Sub-Study must meet these additional criteria:

1. Willing and able to perform the requested procedures for the AVS assessments
2. Current or history of AV block Note: This includes patients with any degree or type of AV block, irrespective of related symptoms and relevance of the AV block for the underlying pacemaker indication

AVS Sub-Study Exclusion Criteria:

After consenting to the main study, patients potentially eligible for the AVS Sub-Study must not meet the following criterion:

1\. Permanent AF

Where it's running

• Sutter Health
  Burlingame, California, United States Recruiting
• UC San Diego Health
  La Jolla, California, United States Recruiting
• MemorialCare Saddleback Medical
  Laguna Hills, California, United States Recruiting
• Cardiology Associates Medical Group
  Ventura, California, United States Recruiting
• South Denver Cardiology
  Littleton, Colorado, United States Recruiting
• Orlando Health Heart & Vascular Institute
  Orlando, Florida, United States Recruiting

Study contacts

• Study coordinator: Jennifer Alkire Project Manager
• Email: US-BIO-LivIQ@biotronik.com
• Phone: 800-547-0394

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SPIKE FLOW endocardial pacing lead safety and performance study

  This study tests whether the SPIKE FLOW temporary endocardial pacing lead is safe and effective in adults needing temporary pacing during heart-related conditions.

  Recruiting at 2 sites FIAB SpA · Acquaviva delle Fonti, Bari and 2 other locations · NCT07820072

• Leadless Conduction System Pacemaker for Chronic Bradycardia

  This study tests a leadless AVEIR CSP pacemaker to see if it safely and reliably keeps heart rhythm in adults who need a pacemaker.

  Recruiting Abbott Medical Devices · Prague · NCT07287423

• Factors Linked to Slow Heart Rate After Pulsed Field Ablation for Atrial Fibrillation

  This study looks for factors that might cause bradycardia during the hospital stay after AF ablation using pulsed field technology.

  Recruiting Wroclaw Medical University · Wroclaw, Lower Silesian Voivodeship · NCT07809347

• Transjugular implantation of a leadless pacemaker (Aveir VR) for ventricular pacing

  This study tests whether placing an Aveir VR leadless pacemaker through the neck vein can safely provide ventricular pacing in adults with bradycardia.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07802119

• 3D Echocardiography to See How CIEDs May Worsen Tricuspid Regurgitation

  This study tests whether different CIEDs (leadless pacemakers, LBBaP, and conventional pacemakers) differ in causing worsening tricuspid regurgitation, using 3D heart imaging.

  Recruiting Samsung Medical Center · Seoul, Seoul · NCT07793916

• Conduction System Pacing Display Research During LBBAP Implant

  Researchers are testing a CSP Display System during left bundle branch area pacing pacemaker implant to see if it accurately shows heart signals compared with a standard ECG.

  Recruiting at 2 sites Medtronic Cardiac Rhythm and Heart Failure · Madurai, Tamil Nadu and 1 other locations · NCT07733960

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.